A Novel Curcumin-Galactomannoside Complex Delivery System Improves Hepatic Function Markers in Chronic Alcoholics: A Double-Blinded, randomized, Placebo-Controlled Study

• Published in: BioMed research international Vol. 2018; no. 2018; pp. 1 - 10
• Main Authors: Maliakel, Balu P., Mulakal, Johannah N., Nair, Saritha S., Thomas, Justin V., Krishnareddy, Naveen T., Krishnakumar, I. M.
• Format: Journal Article
• Language: English
• Published: Cairo, Egypt Hindawi Publishing Corporation 01.01.2018; Hindawi; John Wiley & Sons, Inc
• Subjects: Adult; Alcoholics; Alcoholism; Alcoholism - blood; Alcoholism - drug therapy; Alcoholism - pathology; Alcohols; Antioxidants; Bioavailability; Biomarkers - blood; Cardiovascular disease; Chromatography; Chronic Disease; Clinical Study; Clinical trials; Curcumin; Curcumin - administration & dosage; Double-Blind Method; Drug approval; Drug Delivery Systems - methods; Food; Functional foods & nutraceuticals; gamma-Glutamyltransferase - blood; Good Manufacturing Practice; Herbal medicine; Humans; Inflammation; Interleukin 6; Liver; Liver - metabolism; Liver - pathology; Liver diseases; Male; Markers; Medical research; Metabolism; Metabolites; Middle Aged; Mortality; Novel foods; Oxidative stress; Pathogenesis; Permeability; Randomization; Transaminases; Transaminases - blood; γ-Glutamyltransferase; India
• ISSN: 2314-6133; 2314-6141; 2314-6141
• DOI: 10.1155/2018/9159281

Considering the recent interest in free (unconjugated) curcuminoids delivery, the present study investigated the efficacy of a novel food-grade free-curcuminoids delivery system (curcumin-galactomannoside complex; CGM) in improving the hepatic function markers (inflammation and oxidative stress) in chronic alcoholics. The double-blinded, placebo-controlled study randomized 48 subjects with elevated serum transaminases and gamma-glutamyl transferase (GGT) levels, who were allocated to two groups (n=24) and to receive either placebo or CGM at (250 mg × 2)/day for 8 weeks. While liver function markers (transaminases and GGT) in the placebo group showed an increase (~ 9.5%), CGM group indicated a significant decrease in transaminases (31%) and GGT (29%) from the baseline levels. The beneficial effect of CGM was also clear from the significant increase (p <0.001) in endogenous antioxidants (GSH, SOD, and GPx) and decrease in inflammatory markers (IL-6 and CRP) levels (p <0.001) as compared to both the baseline and placebo group. To summarize, the nutritional intervention of CGM-curcumin was found to offer a significant hepatoprotective effect to attenuate the alcohol induced alterations to hepatic function markers. The Indian Medical Council and Drug Controller General of India approved Clinical Trial Registry No. CTRI/2018/03/012385.